Evidence map›Paper›PMID 40884203›Full record

ArticleHIV medicine2025

Suppressed switch to Bictegravir/emtricitabine/tenofovir alafenamide compared with dolutegravir/lamivudine: Real-world evidence from the OPERA cohort.

Gerald Pierone, Laurence Brunet, Jennifer S Fusco, Michael G Sension, Megan S Dunbar, Joshua Gruber, Douglas T Dieterich, Gregory P Fusco

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in HIV medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Gerald PieroneWhole Family Health Center, Vero Beach, Florida, USA.ORCID https://orcid.org/0000-0003-0159-7243
Laurence BrunetEpividian, Raleigh, North Carolina, USA.ORCID https://orcid.org/0000-0001-8467-4835
Jennifer S FuscoEpividian, Raleigh, North Carolina, USA.ORCID https://orcid.org/0000-0003-1556-811X
Michael G SensionCAN Community Health, Fort Lauderdale, Florida, USA.
Megan S DunbarGilead Sciences, Inc., Foster City, California, USA.ORCID https://orcid.org/0000-0001-9250-5126
Joshua GruberGilead Sciences, Inc., Foster City, California, USA.
Douglas T DieterichMount Sinai Health System, New York, New York, USA.
Gregory P FuscoEpividian, Raleigh, North Carolina, USA.

Funding

Gilead Sciences
6 · The paper itself

Abstract

objectivesTo compare the virologic effectiveness and discontinuation of the commonly prescribed fixed-dose combination 3-drug and 2-drug regimens, bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) and dolutegravir/lamivudine (DTG/3TC), in virologically suppressed individuals in routine clinical care in the US.

methodsFrom the OPERA cohort, ART-experienced, virologically suppressed (viral load <200 copies/mL) adults with HIV who switched to B/F/TAF or DTG/3TC (01AUG2020-30JUN2022) were followed through 31DEC2022, death, loss to follow-up or discontinuation. Cox proportional hazard models with stabilized inverse probability of treatment weights were used to assess the association between regimen and time to confirmed virologic failure (cVF

resultsA total of 3512 B/F/TAF users were followed for a median of 16 months (IQR: 11, 22); 2327 DTG/3TC users were followed for a median of 15 months (IQR: 10, 21). cVF

conclusionsIn this large US cohort, both B/F/TAF and DTG/3TC were well tolerated and effective treatment options among virologically suppressed individuals in routine clinical care, although DTG/3TC tended to be discontinued faster than B/F/TAF.

Indexed as

AdenineAnti-HIV AgentsEmtricitabineHeterocyclic Compounds, 3-RingHeterocyclic Compounds, 4 or More RingsHIV InfectionsLamivudineTenofovirAdultAlanineAmidesCohort StudiesDolutegravirDrug CombinationsDrug SubstitutionFemaleAdenineAlanineAmidesAnti-HIV AgentsbictegravirDolutegravirDrug CombinationsEmtricitabineHeterocyclic Compounds, 3-RingHeterocyclic Compounds, 4 or More RingsLamivudineOxazinesPiperazinesPyridonesTenofovirtenofovir alafenamidebictegravircohortdolutegravir/lamivudineregimen discontinuationvirologic failure

Identifiers

PMID40884203
PMCPMC12579892

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.